News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
651,199 Results
Type
Article (49892)
Company Profile (70)
Press Release (601215)
Multimedia
Podcasts (179)
Webinars (20)
Section
Business (203282)
Career Advice (2825)
Deals (32892)
Drug Delivery (167)
Drug Development (76457)
Employer Resources (179)
FDA (15793)
Job Trends (14570)
News (308091)
Policy (30641)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Genetown Standard (3)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2879)
Academic (1)
Accelerated approval (58)
ADA (49)
Adcomms (42)
Allergies (197)
Alliances (43696)
ALS (236)
Alzheimer's disease (1962)
Antibody-drug conjugate (ADC) (558)
Approvals (16208)
Artificial intelligence (773)
ASCO (327)
Autoimmune disease (364)
Automation (63)
Bankruptcy (332)
Best Places to Work (11409)
BIO (66)
BIOSECURE Act (23)
Biosimilars (249)
Biotechnology (59)
Bladder cancer (210)
Brain cancer (79)
Breast cancer (841)
Cancer (6548)
Cardiovascular disease (549)
Career advice (2407)
Career pathing (53)
CAR-T (374)
CDC (75)
Celiac Disease (2)
Cell therapy (1002)
Cervical cancer (58)
Clinical research (67261)
Collaboration (2254)
Commercialization (4)
Company closure (7)
Compensation (1554)
Complete response letters (109)
COVID-19 (2945)
CRISPR (116)
C-suite (1395)
Cystic fibrosis (160)
Data (8792)
Decentralized trials (3)
Denatured (48)
Depression (198)
Dermatology (109)
Diabetes (690)
Diagnostics (6849)
Digital health (62)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (388)
Drug pricing (230)
Drug shortages (39)
Duchenne muscular dystrophy (321)
Earnings (66458)
Editorial (80)
Employer branding (23)
Employer resources (164)
Events (88355)
Executive appointments (1246)
FDA (19887)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (22)
Frontotemporal dementia (34)
Funding (1871)
Gene editing (262)
Generative AI (68)
Gene therapy (814)
GLP-1 (1227)
Government (5012)
Grass and pollen (6)
Guidances (424)
Healthcare (18833)
Hematology (191)
HIV (104)
Huntington's disease (71)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (120)
Immunology and inflammation (333)
Immuno-oncology (117)
Indications (224)
Infectious disease (3336)
Inflammatory bowel disease (232)
Inflation Reduction Act (16)
Influenza (149)
Intellectual property (332)
Interviews (526)
IPO (15833)
IRA (57)
Job creations (3428)
Job search strategy (1972)
JPM (70)
Kidney cancer (27)
Labor market (104)
Layoffs (655)
Leadership (56)
Legal (6638)
Liver cancer (108)
Longevity (34)
Lung cancer (878)
Lymphoma (481)
Machine learning (65)
Management (64)
Manufacturing (1220)
Marketing (10)
MASH (223)
Medical affairs (1)
Medical device (13079)
Medtech (13261)
Mergers & acquisitions (18463)
Metabolic disorders (1784)
mRNA (264)
Multiple sclerosis (212)
NASH (24)
Neurodegenerative disease (517)
Neuropsychiatric disorders (124)
Neuroscience (3711)
Neurotech (1)
NextGen: Class of 2026 (6610)
Non-profit (4622)
Now hiring (59)
Obesity (845)
Opinion (362)
Ovarian cancer (244)
Pain (290)
Pancreatic cancer (360)
Parkinson's disease (406)
Partnered (35)
Patents (663)
Patient recruitment (813)
Peanut (65)
People (62978)
Pharmaceutical (23)
Pharmacy benefit managers (35)
Phase 1 (20595)
Phase 2 (29661)
Phase 3 (22754)
Pipeline (10275)
Policy (388)
Postmarket research (2263)
Preclinical (8604)
Press Release (69)
Prostate cancer (343)
Psychedelics (78)
Radiopharmaceuticals (359)
Rare diseases (1289)
Real estate (5311)
Recruiting (77)
Regulatory (25178)
Reports (46)
Research institute (2556)
Resumes & cover letters (442)
Rett syndrome (47)
RNA editing (26)
RSV (95)
Schizophrenia (193)
Series A (315)
Series B (241)
Service/supplier (3)
Sickle cell disease (129)
Special edition (31)
Spinal muscular atrophy (182)
Sponsored (51)
Startups (3416)
State (2)
Stomach cancer (19)
Supply chain (141)
Tariffs (96)
The Weekly (128)
Vaccines (1277)
Venture capital (131)
Weight loss (579)
Women's health (136)
Worklife (25)
Date
Last 7 days (437)
Last 30 days (1760)
Last 365 days (29250)
2026 (17015)
2025 (28966)
2024 (33498)
2023 (37917)
2022 (48872)
2021 (53047)
2020 (52219)
2019 (45907)
2018 (34883)
2017 (31631)
2016 (30139)
2015 (34707)
2014 (25824)
2013 (20958)
2012 (22204)
2011 (22896)
2010 (19874)
Location
Africa (881)
Alabama (101)
Alaska (7)
Arizona (277)
Arkansas (13)
Asia (39712)
Australia (6904)
California (13031)
Canada (3875)
China (1593)
Colorado (555)
Connecticut (594)
Delaware (426)
Europe (91584)
Florida (2054)
Georgia (425)
Hawaii (2)
Idaho (60)
Illinois (1099)
India (102)
Indiana (639)
Iowa (24)
Japan (609)
Kansas (134)
Kentucky (44)
Louisiana (54)
Maine (68)
Maryland (1541)
Massachusetts (9310)
Michigan (350)
Minnesota (688)
Mississippi (6)
Missouri (142)
Montana (34)
Nebraska (26)
Nevada (147)
New Hampshire (84)
New Jersey (3570)
New Mexico (30)
New York (3572)
North Carolina (1651)
North Dakota (11)
Northern California (6516)
Ohio (400)
Oklahoma (19)
Oregon (38)
Pennsylvania (2585)
Puerto Rico (33)
Rhode Island (50)
South America (1183)
South Carolina (89)
South Dakota (2)
Southern California (5293)
Tennessee (223)
Texas (2160)
United States (46546)
Utah (387)
Vermont (2)
Virginia (340)
Washington D.C. (77)
Washington State (1054)
West Virginia (4)
Wisconsin (141)
Wyoming (2)
651,199 Results for "synteracthcr formerly known as synteract".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Mighty Therapeutics, Formerly Stealth BioTherapeutics, Announces New Name Honoring the Mitochondrial Disease Community
June 16, 2026
·
6 min read
Metabolic disorders
Ascendis Skids as FDA Detects Death in Patient Formerly on Yorvipath
The death occurred in a patient who had a complex medical background and who was being managed with several drugs, according to RBC Capital.
October 21, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Allotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell Cancers
July 8, 2026
·
5 min read
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Press Releases
BreezeBio (Formerly GenEdit) Announces Series B Financing to Advance Internal Pipeline of Precision Genetic Medicines
February 25, 2026
·
4 min read
Mergers & acquisitions
Revolution, Ascendis Named Top Buyout Targets as Industry Awaits The Big One
Prime biotech buyout targets such as Revolution Medicines and Ascendis Pharma have recently found themselves in the middle of acquisition rumors—though no deals have panned out so far.
March 19, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Recludix Pharma Announces Preclinical Data Demonstrating Efficacy Comparable to Monoclonal Antibodies Targeting IL-4/IL-13 Signaling Pathways and Differentiated Safety Profile of Oral STAT6 Inhibitor REX-8756 (also known as SAR448755) in a Model of Atopic Dermatitis
May 17, 2026
·
3 min read
Press Releases
Biolojic Design Earns Preclinical Milestone from Teva for First AI-Designed Multibody in Autoimmune Disease, TEV ‘325 (formerly BD9)
March 25, 2026
·
2 min read
Pipeline
Ascendis retreats to rare endocrinology wheelhouse as cancer plans falter
Before discontinuing the asset, Ascendis Pharma was studying onvapegleukin alfa in advanced or metastatic solid tumors, demonstrating a three- to four-month overall survival advantage over historical controls.
May 8, 2026
·
2 min read
·
Tristan Manalac
Psychedelics
Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
Eli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst cautioned, however, that the transaction should not be seen as “supporting a uniform re-rating of every psychedelic developer.”
July 20, 2026
·
3 min read
·
Heather McKenzie
1 of 65,120
Next
